Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC.ATOS · Entity 7556 | Director | May 12, 2026 | May 14, 2026 |
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Director | September 02, 2026 | September 04, 2026 |
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Chief Financial Officer | June 15, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATOSSA THERAPEUTICS, INC.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2026-05-12 transaction · row 1
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 10,000 · Balance 10,000 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026.
Actinium Pharmaceuticals, Inc.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,116 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Grant · Acquired 62,800 · Balance 63,116 F1: Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2036-09-02 | Direct | 94,200 |
Reported balance
After 2026-09-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-02 · Grant · Acquired 94,200 · Balance 94,200 F2: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant.
F2: The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant.
BioXcel Therapeutics, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,335 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Exercise / conversion · Acquired 35 · Balance 26,335 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 212 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Exercise / conversion · Disposed 35 · Balance 212 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2020 Filed May 19, 2020 18:06 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001437749-20-011263 · rdgdoc.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-05-15 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 4:30 p.m. (ET) on May 15, 2020 with an exercise price of $1.70, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| July 12, 2019 Filed Jul 16, 2019 21:19 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 250,000 | $0.23 Strike: $0.23 | $58,000.00 |
DisclosureSEC source: 0001213900-19-012891 · ownership.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-07-12 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| May 17, 2019 Filed May 22, 2019 00:07 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001437749-19-010647 · rdgdoc.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-05-17 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 9:00 a.m. (ET) on May 17, 2019 with an exercise price of $2.52, representing the most recently reported closing stock price at the time of grant. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 14:49 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 500 | $5.20 | $2,599.95 |
DisclosureSEC source: 0001104659-18-071215 · a4.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Read SEC document |
| November 30, 2018 Filed Nov 30, 2018 22:36 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 500 | $5.00 | $2,500.00 |
DisclosureSEC source: 0001104659-18-070876 · a4.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 19:30 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 500 | $5.00 | $2,500.00 |
DisclosureSEC source: 0001104659-18-070793 · a4.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 21:04 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 75,000 | $0.78 Strike: $0.78 | $58,717.50 |
DisclosureSEC source: 0001213900-18-009311 · ownership.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:03 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001615774-18-005998 · s111132_form4.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 21:12 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Options · Derivative | 32,232 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001104659-18-017149 · a4.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,130 Underlying: Common Stock · 32,232 shares Expires 2028-03-12 F1 · derivative.exercise_date: The shares underlying this stock option vest as follows: 8,058 shares shall vest on March 12, 2019 and the remaining 24,174 shares shall vest monthly over 36 months from March 12, 2019 through March 12, 2022. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:24 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherSeries B Warrants · Derivative | 5,250 | $0.50 Strike: $0.70 | $2,625.00 |
DisclosureSEC source: 0001213900-18-002730 · f4030618steinhart_actinium.xml · derivative · entry 3 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2020-09-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:24 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherSeries A Warrants · Derivative | 1,750 | $0.50 Strike: $0.60 | $875.00 |
DisclosureSEC source: 0001213900-18-002730 · f4030618steinhart_actinium.xml · derivative · entry 2 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires 2019-03-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:24 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherCommon Stock | 7,000 | $0.50 | $3,500.00 |
DisclosureSEC source: 0001213900-18-002730 · f4030618steinhart_actinium.xml · nonDerivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Read SEC document |
| May 24, 2017 Filed May 26, 2017 17:53 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 49,531 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001615774-17-002747 · s106365_form4.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,062 Underlying: Common Stock · 49,531 shares Expires 2027-05-24 F1 · derivative.exercise_date: The options shall vest on a quarterly basis over the next 12 months. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:10 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 75,000 | $1.39 Strike: $1.39 | $104,250.00 |
DisclosureSEC source: 0001213900-17-002453 · f4031417steinhart_actinium.xml · derivative · entry 1 Steinhart Richard I · CIK 0001293789 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.